Can a patient get the Harmony prenatal test after 13 weeks of gestation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Harmony Prenatal Test After 13 Weeks

Yes, a patient can get the Harmony prenatal test after 13 weeks of gestation, as cell-free DNA testing can be performed throughout pregnancy and is not restricted to the first trimester. 1, 2

Optimal Timing Considerations

The Harmony test (a cell-free DNA/NIPT platform) can technically be performed from 10 weeks gestation onward without an upper gestational age limit. 1, 2 However, the timing of testing involves several practical considerations:

Performance Characteristics by Gestational Age

  • Cell-free DNA testing maintains high accuracy throughout pregnancy, with detection rates for trisomy 21 exceeding 99% in singleton pregnancies regardless of when the sample is drawn after 10 weeks. 3, 2

  • First-trimester biochemical screening (PAPP-A, free β-hCG) performs optimally between 11-13 weeks, with sensitivity declining after 13 completed weeks for combined first-trimester screening approaches. 4 This is relevant only if combining NIPT with traditional screening, not for NIPT alone.

  • The Harmony test specifically has been validated from 10 weeks gestation, with the initial study reporting results obtained in 94.8% of twin pregnancies tested during the 10-14 week window. 3

Practical Advantages of Testing After 13 Weeks

  • Lower spontaneous miscarriage risk: Testing at 13 weeks or later avoids performing screening on pregnancies that would have miscarried naturally, reducing unnecessary anxiety and follow-up testing. 5

  • Immediate diagnostic confirmation available: After 15 weeks, amniocentesis becomes the standard diagnostic option if NIPT results are high-risk, allowing for streamlined follow-up without the need for chorionic villus sampling (which is typically performed between 10-13 weeks 6 days). 4, 5

  • Higher fetal fraction: As pregnancy advances, the fetal fraction in maternal blood generally increases, potentially reducing the "no-call" rate due to insufficient fetal fraction. 6

Important Caveats

Test Failure and Redraw Considerations

  • Maternal weight significantly impacts test success: Higher maternal weight decreases the odds of obtaining a result (OR 0.988 per kg), which is particularly relevant for samples drawn at any gestational age. 6

  • If initial testing fails due to insufficient fetal fraction, waiting longer between draws increases success rates (OR 1.040 per day of interval), but this must be balanced against advancing gestational age and clinical urgency. 6

Screening vs. Diagnostic Testing

  • NIPT is a screening test, not diagnostic: Regardless of gestational age at testing, positive results require confirmation with diagnostic testing (amniocentesis after 15 weeks) before making irreversible pregnancy management decisions. 2, 5

  • All patients should be offered screening regardless of age or baseline risk, and NIPT represents the most sensitive and specific screening option for common aneuploidies. 2

Twin Pregnancies

  • The Harmony test is validated for twin pregnancies, though detection rates are slightly lower than in singletons (95% for trisomy 21 in twins vs. 99% in singletons), and this performance is maintained when testing occurs in the 10-14 week window. 3

Clinical Bottom Line

There is no upper gestational age limit for performing the Harmony prenatal test after 13 weeks. The test can be performed at any point in the second or third trimester if clinically indicated. However, testing between 13-14 weeks may represent an optimal window, balancing early reassurance with reduced spontaneous loss rates and immediate access to amniocentesis for confirmation if needed. 5

References

Research

Pearls and Pitfalls of First-Trimester US Screening and Prenatal Testing: A Pictorial Review.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2025

Research

Cell-free DNA testing of maternal blood in screening for trisomies in twin pregnancy: updated cohort study at 10-14 weeks and meta-analysis.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2021

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Factors associated with obtaining results on repeat cell-free DNA testing in samples redrawn due to insufficient fetal fraction.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.